Amanta Healthcare IPO Fully Subscribed Within Hours of Bidding

“Amanta's strengths include a well-established market presence, diverse product offerings, and extensive manufacturing capabilities at its WHO-GMP certified facility in Kheda, Gujarat.”

“Their manufacturing facility has a cumulative capacity of 33.19 units for LVP, SVP, and SteriPort, with 96 per cent utilization in FY25.”

“While valuations appear rich, Amanta Healthcare offers a differentiated play on India’s growing sterile injectables and IV fluids market.”

“Its established manufacturing expertise, strong domestic and export footprint, and capacity expansion plans provide growth visibility.”

“We expect Amant Healthcare to gradually offset this through improved scale, a stronger top line, and a more accretive product mix, which together should structurally reinforce the business.”

“Thus, we recommend a 'subscribe' rating for this issue from a medium to long-term perspective.”

“Amantas' strengths of experienced promoter and established market position, large distributor network, proposed capacity expansion plans along with diverse product profile is offset by high debt to equity ratio, exposure to intense competition, susceptibility of operating margins to volatility in prices of packing material, we recommend a ‘may subscribe’ to this IPO.”